Description

FLAVEDON OD 80 MG

Indications

FLAVEDON OD 80 MG is primarily indicated for the management of chronic stable angina pectoris. It is also used in the treatment of various cardiovascular conditions, including ischemic heart disease. The formulation is designed to provide long-lasting effects, making it suitable for patients requiring consistent therapeutic outcomes in the management of their cardiovascular health.

Mechanism of Action

FLAVEDON OD contains the active ingredient Trimetazidine, which acts as a metabolic modulator. It enhances myocardial energy metabolism by optimizing glucose utilization and fatty acid oxidation. By doing so, FLAVEDON OD improves the efficiency of energy production in cardiac cells, particularly under ischemic conditions. This mechanism helps to maintain cardiac function and reduce the frequency and severity of angina episodes, thereby improving the overall quality of life for patients with chronic stable angina.

Pharmacological Properties

Trimetazidine, the active component of FLAVEDON OD, is known for its cardioprotective properties. It exhibits anti-ischemic effects by stabilizing cellular metabolism in the heart muscle. The pharmacokinetics of FLAVEDON OD show that it is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 3 to 4 hours. The drug has a half-life of approximately 5 to 7 hours, allowing for once-daily dosing in the extended-release formulation. Additionally, FLAVEDON OD is primarily excreted unchanged in the urine, indicating minimal hepatic metabolism.

Contraindications

FLAVEDON OD is contraindicated in patients with known hypersensitivity to Trimetazidine or any of the excipients in the formulation. It should not be used in patients with Parkinson’s disease or other movement disorders, as it may exacerbate these conditions. Furthermore, the use of FLAVEDON OD is not recommended in patients with severe renal impairment, as the drug is primarily excreted through the kidneys, and accumulation may lead to increased side effects.

Side Effects

Like all medications, FLAVEDON OD may cause side effects, although not everyone will experience them. Common side effects include dizziness, headache, and gastrointestinal disturbances such as nausea or abdominal pain. Rare but serious side effects may include allergic reactions, including rash, pruritus, and angioedema. Patients should be advised to report any unusual symptoms or side effects to their healthcare provider promptly. It is essential to weigh the benefits of treatment against the potential risks when prescribing FLAVEDON OD.

Dosage and Administration

The recommended dosage of FLAVEDON OD is one tablet of 80 mg taken once daily. It is advised to take the medication with a meal to enhance absorption and minimize gastrointestinal discomfort. The tablet should be swallowed whole and not chewed or crushed, as this may alter the extended-release properties of the formulation. Dosage adjustments may be necessary in patients with renal impairment, and it is crucial to follow the prescribing physician’s recommendations for individual patient needs.

Interactions

FLAVEDON OD may interact with other medications, potentially altering their effects or increasing the risk of adverse reactions. Notably, caution should be exercised when administering FLAVEDON OD alongside other drugs that affect the central nervous system, as the risk of side effects may be amplified. Additionally, concurrent use with other antianginal agents should be monitored closely to avoid additive effects. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to ensure safe and effective treatment.

Precautions

Before initiating treatment with FLAVEDON OD, a thorough medical history should be taken to identify any potential contraindications or precautions. Special caution is advised in elderly patients and those with pre-existing renal conditions, as they may be more susceptible to side effects. Regular monitoring of renal function may be warranted during treatment. Patients should also be advised to avoid abrupt discontinuation of the medication, as this may precipitate an exacerbation of angina symptoms. It is essential for patients to adhere to their prescribed treatment regimen and attend follow-up appointments to assess the effectiveness and safety of FLAVEDON OD.

Clinical Studies

Clinical studies have demonstrated the efficacy of FLAVEDON OD in reducing the frequency of angina attacks and improving exercise tolerance in patients with chronic stable angina. In a randomized, double-blind, placebo-controlled trial, patients receiving FLAVEDON OD reported a significant reduction in angina episodes compared to those receiving a placebo. Moreover, the medication was well-tolerated, with a side effect profile consistent with previous findings. Long-term studies have suggested that FLAVEDON OD may also contribute to improved quality of life and functional status in patients with ischemic heart disease.

Conclusion

FLAVEDON OD 80 MG is a valuable therapeutic option for patients suffering from chronic stable angina pectoris and related cardiovascular conditions. Its unique mechanism of action as a metabolic modulator provides a distinct approach to managing angina symptoms and improving cardiac efficiency. While generally well-tolerated, it is essential for healthcare providers to consider individual patient factors, potential drug interactions, and contraindications when prescribing this medication. Ongoing clinical evaluation and patient education are crucial to ensure optimal therapeutic outcomes and enhance the quality of life for patients using FLAVEDON OD.